Regeneron Pharmaceuticals, Inc. REGN reported first-quarter 2025 adjusted earnings per share (EPS) of $8.22, which missed the Zacks Consensus Estimate of $8.43. The reported figure was down 14% from ...

This was the stock's second consecutive day of gains.

Regeneron (REGN) reported $3.03 billion in revenue for the quarter ended March 2025, representing a year-over-year decline of 3.7%. EPS of $8.22 for the same period compares to $9.55 a year ago. The ...

Regeneron earns a buy rating with strong profit margins, low debt, and growth potential. Discover why shares may see a 39% ...

Shares of Regeneron Pharmaceuticals Inc. REGN advanced 2.39% to $584.99 Thursday, on what proved to be an all-around positive ...

2025 when UBS changed their price target from $1130 to $738 for Regeneron Pharmaceuticals Inc. Analysts arrive at stock ratings after doing extensive research, which includes going through public ...

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Regeneron? Access our full analysis report here ...

Return on Equity (ROE): Regeneron Pharmaceuticals's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.13% ROE, the company ...

Wall Street analysts expect Regeneron (REGN ... trends in earnings estimate revision and the short-term price performance of a stock. While investors typically use consensus earnings and revenue ...

Regeneron Pharmaceuticals stock was among the biggest S&P 500 and Nasdaq decliners Tuesday after the biotech firm reported first-quarter sales—especially those of its key Eylea eye disease drug ...

For the first time since 2022, REGN has dipped below ... with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results.

Regeneron's performance in the first quarter was dismal ... NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer ...